TNFRSF17, also known as B-cell maturation antigen (BCMA), plays a critical role in the survival and differentiation of plasma cells and has emerged as a promising therapeutic target for multiple myeloma and other plasma cell disorders (61–74). Here, TNFRSF17 is linked to plasma cell neoplasm.